Literature DB >> 15930347

Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer.

Catherine Murphy1, Maryalice McGurk, Johanna Pettigrew, Alfredo Santinelli, Roberta Mazzucchelli, Patrick G Johnston, Rodolfo Montironi, David J J Waugh.   

Abstract

PURPOSE: We characterized interleukin-8 (IL-8) and IL-8 receptor expression (CXCR1 and CXCR2) in prostate cancer to address their significance to this disease. EXPERIMENTAL
DESIGN: Immunohistochemistry was conducted on 40 cases of human prostate biopsy containing histologically normal and neoplastic tissue, excised from patients with locally confined or invasive androgen-dependent prostate cancer, and 10 cases of transurethral resection of the prostate material from patients with androgen-independent disease.
RESULTS: Weak to moderate IL-8 expression was strictly localized to the apical membrane of normal prostate epithelium. In contrast, membranous expression of IL-8, CXCR1, and CXCR2 was nonapical in cancer cells of Gleason pattern 3 and 4, whereas circumferential expression was present in Gleason pattern 5 and androgen-independent prostate cancer. Each of IL-8, CXCR1, and CXCR2 were also increasingly localized to the cytoplasm of cancer cells in correlation with advancing stage of disease. Cytoplasmic expression (but not apical membrane expression) of IL-8 in Gleason pattern 3 and 4 cancer correlated with Ki-67 expression (R = 0.79; P < 0.001), cyclin D1 expression (R = 0.79; P < 0.001), and microvessel density (R = 0.81; P < 0.001). In vitro studies on androgen-independent PC3 cells confirmed the mitogenic activity of IL-8, increasing the rate of cell proliferation through activation of both CXCR1 and CXCR2 receptors.
CONCLUSIONS: We propose that the concurrent increase in IL-8 and IL-8 receptor expression in human prostate cancer induces autocrine signaling that may be functionally significant in initiating and promoting the progression of prostate cancer by underpinning cell proliferation and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930347     DOI: 10.1158/1078-0432.CCR-04-1518

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  93 in total

1.  Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer.

Authors:  Shi-Liang Gui; Li-Chen Teng; Shu-Qiu Wang; Shuang Liu; Ying-Li Lin; Xiao-Lian Zhao; Lei Liu; Hong-Yu Sui; Yang Yang; Li-Chun Liang; Mo-Lin Wang; Xin-Yi Li; Yu Cao; Feng-Ying Li; Wei-Qun Wang
Journal:  Int Urol Nephrol       Date:  2016-02-02       Impact factor: 2.370

2.  Inducible silencing of protein kinase D3 inhibits secretion of tumor-promoting factors in prostate cancer.

Authors:  Courtney R LaValle; Liyong Zhang; Shuping Xu; Julie L Eiseman; Q Jane Wang
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

3.  IL-8 is upregulated in cervical cancer tissues and is associated with the proliferation and migration of HeLa cervical cancer cells.

Authors:  Linlin Jia; Fengying Li; Mingliang Shao; Wei Zhang; Chunbin Zhang; Xiaolian Zhao; Haiyan Luan; Yaling Qi; Pengxia Zhang; Lichun Liang; Xiuyue Jia; Kun Zhang; Yan Lu; Zhe Yang; Xiulin Zhu; Qi Zhang; Jiwei Du; Weiqun Wang
Journal:  Oncol Lett       Date:  2017-11-10       Impact factor: 2.967

4.  A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).

Authors:  Ronald S Boshuizen; Catherine Marsden; Johan Turkstra; Christine J Rossant; Jerry Slootstra; Clive Copley; Klaus Schwamborn
Journal:  MAbs       Date:  2014       Impact factor: 5.857

5.  Integrated in silico and 3D in vitro model of macrophage migration in response to physical and chemical factors in the tumor microenvironment.

Authors:  Sharon Wei Ling Lee; R J Seager; Felix Litvak; Fabian Spill; Je Lin Sieow; Penny Hweixian Leong; Dillip Kumar; Alrina Shin Min Tan; Siew Cheng Wong; Giulia Adriani; Muhammad Hamid Zaman; And Roger D Kamm
Journal:  Integr Biol (Camb)       Date:  2020-04-20       Impact factor: 2.192

Review 6.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

7.  Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappaB synergy.

Authors:  Jiajia Ma; Zijia Ren; Yang Ma; Lu Xu; Ying Zhao; Chaogu Zheng; Yinghui Fang; Ting Xue; Baolin Sun; Weihua Xiao
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

8.  Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.

Authors:  Kaouther Snoussi; Wijden Mahfoudh; Noureddine Bouaouina; Meriem Fekih; Hedi Khairi; Ahmed N Helal; Lotfi Chouchane
Journal:  BMC Cancer       Date:  2010-06-12       Impact factor: 4.430

9.  Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs.

Authors:  Rajendra K Singh; Bal L Lokeshwar
Journal:  Mol Cancer       Date:  2009-07-31       Impact factor: 27.401

10.  Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.

Authors:  A Seaton; P J Maxwell; A Hill; R Gallagher; J Pettigrew; R H Wilson; D J J Waugh
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.